Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan focuses on selecting promising assets with well-understood biology and proof-of-concept data in in vivo models from academia, industry and other sources. Data generated during a rigorous de-risking process enables formation of stand-alone companies and strategic partnerships.